TP53 and glioma: High TP53 glioma samples were more sensitive to vorinostat, elesclomol, gefitinib, AICAR, axitinib, and bosutinib.<h4>Conclusion</h4>The TP53 score based on the P53 signaling pathway can describe the heterogeneity of glioma samples and distinguish different immune microenvironment characteristics and prognostic features.